Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Regeneron Pharmaceuticals is paying Sanofi 900 million dollars upfront plus an 11 percent royalty on global net sales to take complete control of Libtayo, the…
Regeneron Pharmaceuticals Inc said on Thursday it would buy back rights to its cancer drug Libtayo from Sanofi for about $1.1 billion in a deal that gives the…
On October 8, 2025, the FDA approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with CSCC at high risk of recurrence after surgery and…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Regeneron acquired Sanofi's stake in their Libtayo (cemiplimab) collaboration, gaining exclusive worldwide development, commercialization and manufacturing rights. Sanofi received $900M upfront, an 11% royalty on worldwide net sales, a $100M regulatory milestone, and up to $100M in sales-related milestones over two years. Closed July 1, 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) (this deal) | 2022 | $1.1B | — |
| Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. | 2019 | $1.0B | 77 |
| Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. | 2026 | $4.0B | 62 |
| Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. | 2025 | $256M | — |
| Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. | 2026 | $2.3B | — |
| Regeneron Pharmaceuticals, Inc. / Telix Pharmaceuticals Limited | 2026 | $2.1B | — |
| Regeneron Pharmaceuticals, Inc. / Tessera Therapeutics, Inc. | 2025 | $275M | — |
← Browse all deals · How we score deals
More: 2022 deals · Regeneron Pharmaceuticals, Inc. deals · Oncology deals